Sonoma Pharmaceuticals Inc [NASDAQ: SNOA] stock went on an upward path that rose over 4.95% on Tuesday, amounting to a one-week price decrease of less than -4.90%.
Over the last 12 months, SNOA stock dropped by -25.61%. The one-year Sonoma Pharmaceuticals Inc stock forecast points to a potential upside of 86.29. The average equity rating for SNOA stock is currently 1.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $3.77 million, with 1.62 million shares outstanding and 1.59 million shares in the current float. Compared to the average trading volume of 1.56M shares, SNOA stock reached a trading volume of 5568403 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Sonoma Pharmaceuticals Inc [SNOA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SNOA shares is $17.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SNOA stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Average True Range (ATR) for Sonoma Pharmaceuticals Inc is set at 0.32, with the Price to Sales ratio for SNOA stock in the period of the last 12 months amounting to 0.27. The Price to Book ratio for the last quarter was 0.77, with the Price to Cash per share for the same quarter was set at 3.24. Price to Free Cash Flow for SNOA in the course of the last twelve months was 28.98 with Quick ratio for the last quarter at 2.44.
SNOA Stock Performance Analysis:
Sonoma Pharmaceuticals Inc [SNOA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.90. With this latest performance, SNOA shares dropped by -33.05% in over the last four-week period, additionally sinking by -20.48% over the last 6 months – not to mention a drop of -25.61% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SNOA stock in for the last two-week period is set at 46.99, with the RSI for the last a single of trading hit 48.26, and the three-weeks RSI is set at 46.94 for Sonoma Pharmaceuticals Inc [SNOA]. The present Moving Average for the last 50 days of trading for this stock 2.58, while it was recorded at 2.36 for the last single week of trading, and 3.44 for the last 200 days.
Insight into Sonoma Pharmaceuticals Inc Fundamentals:
Sonoma Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.44 and a Current Ratio set at 3.29.
Sonoma Pharmaceuticals Inc [SNOA] Institutonal Ownership Details
There are presently around $1.26%, or 1.27%% of SNOA stock, in the hands of institutional investors. The top three institutional holders of SNOA stocks are: CITADEL ADVISORS LLC with ownership of 0.2 million shares, which is approximately 1.2504%. GEODE CAPITAL MANAGEMENT, LLC, holding 86644.0 shares of the stock with an approximate value of $$18385.0 in SNOA stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $$9611.0 in SNOA stock with ownership which is approximately 0.2902%.
